Antisense inhibition of ICAM-1, E-selectin, and CMV IE1/IE2
AssigneeIsis Pharmaceuticals, Inc.
InventorsBrenda Baker, C. Frank Bennett, Kevin P. Anderson
Life of this patent
Estimating the term…
Abstract
Compositions and methods are provided for inhibiting the translation of a capped target mRNA. Antisense oligomers of the invention are targeted to the 5' cap region of the target mRNA and include oligonucleosides, PNAs, or oligonucleotides modified at the 2' position of the sugar. Preferably said oligomers inhibit protein translation directly via interference with ribosome assembly.
Claims4
A composition for inhibiting the translation of a capped target mRNA encoding ICAM-1, E-selectin or CMV IE1/IE2 comprising an oligomer which is 8-25 bases in length and is selected from the group consisting of:
- an oligonucleotide comprising a modified 2'-position;
- an oligonucleoside;
- or a peptide-nucleic acid oligomer;
- said oligomer being specifically hybridizable with a 5' cap region of a capped target mRNA which includes at least one of the first 20 nucleotides at the 5' terminus of said target mRNA, and being capable of interfering with ribosome assembly on the mRNA wherein said target mRNA encodes ICAM-1, E-selectin or CMV IE1/IE2.
A composition for inhibiting the translation of a capped target mRNA encoding ICAM-1, E-selectin or CMV IE1/IE2 comprising an oligonucleotide having SEQ ID NO:
- 1 or 2, SEQ ID NO:
- 3, or SEQ ID NO:
- 5, 6, 7 or 8, respectively, wherein said oligonucleotide has a 2'-OCH.sub.2 CH.sub.2 OCH.sub.3 modification on each 3'-deoxy sugar moiety.
Dependencies are inferred from the claim text.